← Back to Search

Unknown

JAB-8263 for Solid Tumors

Phase 1

Waitlist Available

Research Sponsored by Jacobio Pharmaceuticals Co., Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up approximately 2.5 years

Awards & highlights

Study Summary

This trial is testing a new cancer drug to see what dose is safe and how it affects people with advanced solid tumors.

Eligible Conditions

Solid Tumors, Adult

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ approximately 2.5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~approximately 2.5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and approximately 2.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Find Recommended Phase 2 Dose (RP2D) of JAB-8263

Number of participants with dose limiting toxicities

Secondary outcome measures

Area under the curve

Cmax

Duration of response ( DOR )

+4 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: JAB-8263Experimental Treatment1 Intervention

Monotherapy, dose escalation

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jacobio Pharmaceuticals Co., Ltd.Lead Sponsor

18 Previous Clinical Trials

1,540 Total Patients Enrolled

Jacobio PharmaceuticalsStudy DirectorJacobio Pharmaceuticals

9 Previous Clinical Trials

688 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does this experiment strive to improve patient outcomes?

"This trial, which is slated to last for two-and-a-half years, seeks to identify the appropriate dosage of JAB-8263. Secondary aims include assessing duration of response (DOR), peak plasma concentration (Cmax) and adverse events associated with treatment."

Answered by AI

What is the target enrollment size of this experiment?

"Jacobio Pharmaceuticals Co., Ltd. is the sponsor responsible for running this trial, which requires 30 participants who meet its inclusion criteria. The two primary sites are Tennessee Oncology Nashville in Nashville, Tennessee and SCRI HealthONE in Denver, Colorado."

Answered by AI

Is the recruitment period open for this experiment?

"On clinicaltrials.gov, the data confirms that enrollment is still open for this study which was first launched on November 23rd 2020 and recently revised on March 11th 2022."

Answered by AI

Has the regulatory body authorized JAB-8263 for public use?

"Based on the data currently available, JAB-8263 has been provisionally assigned a safety rating of 1 due to its current stage in clinical trials. At this point, there is minimal evidence for both efficacy and safety."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors

2020. "A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04587479.